Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study

Manuel Alfredo Podesta; Federica Mescia; Anna Ricchiuto; Rona Smith; Martina Tedesco; Matthias Arnaldo Cassia; Julia Holle; Renato Alberto Sinico; Annette Bruchfeld; Iva Gunnarsson; Sophie Ohlsson; Bo Baslund; Zdenka Hruskova; Vladimir Tesar; Gianmarco Sabiu; Maurizio Gallieni; Maria C. Cid; Augusto Vaglio; Lorraine Harper; Mario Cozzolino; Francesco Scolari; David Jayne; Federico Alberici

doi:10.1093/rheumatology/keac716

Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study

Manuel Alfredo Podesta, Federica Mescia^*, Anna Ricchiuto, Rona Smith, Martina Tedesco, Matthias Arnaldo Cassia, Julia Holle, Renato Alberto Sinico, Annette Bruchfeld, Iva Gunnarsson, Sophie Ohlsson, Bo Baslund, Zdenka Hruskova, Vladimir Tesar, Gianmarco Sabiu, Maurizio Gallieni, Maria C. Cid, Augusto Vaglio, Lorraine Harper, Mario CozzolinoFrancesco Scolari, David Jayne, Federico Alberici

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

25 Citationer (Scopus)

Abstract

Objectives Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculitis (AAV). B-cell depletion may increase the risk of hypogammaglobulinemia, potentially leading to severe infections. This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab. Methods This retrospective cohort study included AAV patients treated with rituximab induction in 14 European centres. Severe adverse events (SAEs) were defined as episodes requiring hospitalization or intravenous antibiotics, malignancies, or death. Linear and logistic regression were used to identify predictors of IgG levels and of the risk of hypogammaglobulinemia, defined as IgG

Originalsprog	Engelsk
Tidsskrift	Rheumatology
Vol/bind	62
Udgave nummer	8
Sider (fra-til)	2850–2854
Antal sider	5
ISSN	1462-0324
DOI	https://doi.org/10.1093/rheumatology/keac716
Status	Udgivet - 2023

Adgang til dokumentet

10.1093/rheumatology/keac716

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Podesta, M. A., Mescia, F., Ricchiuto, A., Smith, R., Tedesco, M., Cassia, M. A., Holle, J., Sinico, R. A., Bruchfeld, A., Gunnarsson, I., Ohlsson, S., Baslund, B., Hruskova, Z., Tesar, V., Sabiu, G., Gallieni, M., Cid, M. C., Vaglio, A., Harper, L., ... Alberici, F. (2023). Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study. Rheumatology, 62(8), 2850–2854. https://doi.org/10.1093/rheumatology/keac716

Podesta, MA, Mescia, F, Ricchiuto, A, Smith, R, Tedesco, M, Cassia, MA, Holle, J, Sinico, RA, Bruchfeld, A, Gunnarsson, I, Ohlsson, S, Baslund, B, Hruskova, Z, Tesar, V, Sabiu, G, Gallieni, M, Cid, MC, Vaglio, A, Harper, L, Cozzolino, M, Scolari, F, Jayne, D & Alberici, F 2023, 'Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study', Rheumatology, bind 62, nr. 8, s. 2850–2854. https://doi.org/10.1093/rheumatology/keac716

@article{b6ecd39d33344a4c8da27a493c6cd231,

title = "Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study",

abstract = "Objectives Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculitis (AAV). B-cell depletion may increase the risk of hypogammaglobulinemia, potentially leading to severe infections. This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab. Methods This retrospective cohort study included AAV patients treated with rituximab induction in 14 European centres. Severe adverse events (SAEs) were defined as episodes requiring hospitalization or intravenous antibiotics, malignancies, or death. Linear and logistic regression were used to identify predictors of IgG levels and of the risk of hypogammaglobulinemia, defined as IgG",

keywords = "ANCA-associated vasculitis, rituximab, glucocorticoids, immunosuppression, cyclophosphamide, immunoglobulins, hypogammaglobulinemia, severe adverse events, severe infections, retrospective study, CYCLOPHOSPHAMIDE, GLUCOCORTICOIDS, MAINTENANCE, THERAPY",

author = "Podesta, {Manuel Alfredo} and Federica Mescia and Anna Ricchiuto and Rona Smith and Martina Tedesco and Cassia, {Matthias Arnaldo} and Julia Holle and Sinico, {Renato Alberto} and Annette Bruchfeld and Iva Gunnarsson and Sophie Ohlsson and Bo Baslund and Zdenka Hruskova and Vladimir Tesar and Gianmarco Sabiu and Maurizio Gallieni and Cid, {Maria C.} and Augusto Vaglio and Lorraine Harper and Mario Cozzolino and Francesco Scolari and David Jayne and Federico Alberici",

year = "2023",

doi = "10.1093/rheumatology/keac716",

language = "English",

volume = "62",

pages = "2850–2854",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction

T2 - a multicentre study

AU - Podesta, Manuel Alfredo

AU - Mescia, Federica

AU - Ricchiuto, Anna

AU - Smith, Rona

AU - Tedesco, Martina

AU - Cassia, Matthias Arnaldo

AU - Holle, Julia

AU - Sinico, Renato Alberto

AU - Bruchfeld, Annette

AU - Gunnarsson, Iva

AU - Ohlsson, Sophie

AU - Baslund, Bo

AU - Hruskova, Zdenka

AU - Tesar, Vladimir

AU - Sabiu, Gianmarco

AU - Gallieni, Maurizio

AU - Cid, Maria C.

AU - Vaglio, Augusto

AU - Harper, Lorraine

AU - Cozzolino, Mario

AU - Scolari, Francesco

AU - Jayne, David

AU - Alberici, Federico

PY - 2023

Y1 - 2023

N2 - Objectives Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculitis (AAV). B-cell depletion may increase the risk of hypogammaglobulinemia, potentially leading to severe infections. This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab. Methods This retrospective cohort study included AAV patients treated with rituximab induction in 14 European centres. Severe adverse events (SAEs) were defined as episodes requiring hospitalization or intravenous antibiotics, malignancies, or death. Linear and logistic regression were used to identify predictors of IgG levels and of the risk of hypogammaglobulinemia, defined as IgG

AB - Objectives Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculitis (AAV). B-cell depletion may increase the risk of hypogammaglobulinemia, potentially leading to severe infections. This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab. Methods This retrospective cohort study included AAV patients treated with rituximab induction in 14 European centres. Severe adverse events (SAEs) were defined as episodes requiring hospitalization or intravenous antibiotics, malignancies, or death. Linear and logistic regression were used to identify predictors of IgG levels and of the risk of hypogammaglobulinemia, defined as IgG

KW - ANCA-associated vasculitis

KW - rituximab

KW - glucocorticoids

KW - immunosuppression

KW - cyclophosphamide

KW - immunoglobulins

KW - hypogammaglobulinemia

KW - severe adverse events

KW - severe infections

KW - retrospective study

KW - CYCLOPHOSPHAMIDE

KW - GLUCOCORTICOIDS

KW - MAINTENANCE

KW - THERAPY

U2 - 10.1093/rheumatology/keac716

DO - 10.1093/rheumatology/keac716

M3 - Journal article

C2 - 36562566

SN - 1462-0324

VL - 62

SP - 2850

EP - 2854

JO - Rheumatology

JF - Rheumatology

IS - 8

ER -